In recent times, the Halberd Corporation (OTCMKTS:HALB) is a healthcare sector firm that has managed to grab headlines in a big way due to its innovative work in relation to its extracorporeal methodology meant for treating and also eradicating a spate of diseases.
Earlier on in the week on Monday, the company came into focus after it announced that it had used its methodology to eradicate E. Coli bacteria from the cerebral spinal fluid. Halberd noted that it had done it by way of exposure to tuned laser light in less than 20 minutes, in vitro. It was a major new development not only for the company but also with regards to the fight against E. Coli at a broader level.
At this point in time, the standard with regards to the elimination of E. Coli stands at 10 days when a patient is treated with standard antibiotics. It goes without saying that it was a significant achievement for the company and it is now going to be interesting to see if the Halberd stock gets any kind of traction from investors over the course of the coming days or not. In this regard, it is perhaps also necessary to point out that the company has also managed to work on eliminating a wide range of other antigens using the same methodology.
William A Hartman, who is the Chief Executive Officer, President and Chairman of the company, also spoke about the matter. He noted that the latest breakthrough was another proof about the capabilities of its technology.
However, he was quick to add that people should not be surprised at the string of announcements from the company with regards to elimination of antigens. He noted that the company was not jumping from one disease to the next. There is a method to the whole thing.
